Showing results (911-920 of 3,351) with videos related to
Sort By:
Pageof 336
Pharmacoeconomics|February 12, 2004
A review of health-related workplace productivity loss instrumentsJennifer H Lofland, Laura Pizzi, Kevin D FrickPharmacoeconomics|April 12, 2013
Rituximab for the first-line maintenance treatment of follicular non-Hodgkin's lymphoma : a NICE single technology appraisalJanette Greenhalgh, Adrian Bagust, Angela Boland, et al.Pharmacoeconomics|April 13, 2013
Golimumab for the treatment of ankylosing spondylitis: a NICE single technology appraisalNigel Armstrong, Manuela Joore, Thea van Asselt, et al.Pharmacoeconomics|May 28, 2013
Cost-utility analysis of the newly recommended adjuvant chemotherapy for resectable gastric cancer patients in the 2011 Chinese National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology: Gastric CancerTan Chongqing, Peng Liubao, Zeng Xiaohui, et al.Pharmacoeconomics|July 11, 2013
Unravelling drug reimbursement outcomes: a comparative study of the role of pharmacoeconomic evidence in Dutch and Swedish reimbursement decision makingMargreet Franken, Fredrik Nilsson, Frank Sandmann, et al.Pharmacoeconomics|January 24, 2013
Retigabine for the adjunctive treatment of adults with partial-onset seizures in epilepsy with and without secondary generalization : a NICE single technology appraisalDawn Craig, Stephen Rice, Fiona Paton, et al.Pharmacoeconomics|January 17, 2013
The evaluation and use of economic evidence to inform cancer drug reimbursement decisions in CanadaJean H E Yong, Jaclyn Beca, Jeffrey S HochPharmacoeconomics|April 7, 2012
Eltrombopag for the treatment of chronic immune or idiopathic thrombocytopenic purpura: a NICE single technology appraisalDwayne Boyers, Xueli Jia, David Jenkinson, et al.Pharmacoeconomics|February 2, 2013
Trastuzumab for the treatment of HER2-positive metastatic gastric cancer : a NICE single technology appraisalEldon Spackman, Stephen Rice, Gill Norman, et al.Pageof 336